Press Releases and Events
PRESS RELEASES
Press Release | December 11, 2023
Press Release | November 21, 2023
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
READ MORE
Press Release | November 10, 2023
Crinetics Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | November 7, 2023
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
READ MORE
Press Release | October 10, 2023
Crinetics Announces October 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
Press Release | September 20, 2023
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
READ MORE
Press Release | September 12, 2023
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
READ MORE
Press Release | September 11, 2023
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
READ MORE
Press Release | September 10, 2023
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
READ MORE
Press Release | September 9, 2023
Crinetics Announces September 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
READ MORE
WEBCAST
PRESS RELEASETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
